Beijing Percutek Therapeutics Inc.
Shaping a Healthier Future for Every Family.
Beijing Percutek Therapeutics Inc. is an innovative medical device company based in China, focused on transforming vascular care through advanced stent graft technologies.
We develop, manufacture, and commercialize medical devices across key vascular fields, including aortic, peripheral, and coronary interventions, neurointervention, and vascular access.
As a leading provider of EVAR (Endovascular Aneurysm Repair) and TEVAR (Thoracic Endovascular Aortic Repair) solutions, Percutek adheres to independent research and development to address the unmet clinical needs of patients with complex vascular diseases.
Our innovative portfolio features advanced devices designed for challenging anatomies, such as our unique three-piece endovascular graft constructed from Nitinol and Dacron, which reliably accommodates severe aortic neck angulations up to 75° and neck lengths as short as 10 mm.
Furthermore, our clinical breakthroughs include the NMPA-approved FET Sutureless Integrated Stented Graft (SIS), which is revolutionizing procedural efficiency and treatments for Stanford Type A Aortic Dissections.
Committed to our mission of "Endovascular Precision, Delivered with Care," we continuously collaborate with global clinical experts to bridge gaps in vascular surgery, transform aortic repair, and shape the future of cardiovascular health worldwide.
Products & Global Reach
Countries and Regions Worldwide
Beijing Percutek Therapeutics Inc. has established a broad and comprehensive product portfolio for vascular disease treatment. Supported by a robust proprietary intellectual property platform, the Company has obtained more than 100 granted patents, with multiple core technologies reaching leading domestic standards and advanced international levels. Through innovative design and exceptional quality, its products have gained broad recognition in both China and global markets.
As of April 2026, Percutek has built a portfolio of 32 marketed products and pipeline programs, including 19 products approved by the National Medical Products Administration (NMPA) and two products certified with CE marking.
Today, the Company's products have achieved commercial presence in more than 20 countries and regions worldwide, including Greece, Germany, Italy, Poland, Turkey, Austria, India, Argentina, South Africa, Vietnam, Egypt, CIS region as well as key markets across Eastern Europe and Central America, with its global footprint continuing to expand.
Global Map
Corporate Culture
To be a leader in innovative products and therapies for cardiovascular disease.
Shaping a Healthier Future for Every Family.
Driving innovation, bringing hope to life. Pursuing excellence, shaping the future.
Customer Focus, Innovation-Driven Growth, Agility and Speed, Accountability, Excellence.